Dentistry

Avēsis and Harmony Health Launch Pioneering Salivary Testing Pilot for Patients with Special Healthcare Needs

Retrieved on: 
Wednesday, April 24, 2024
Other Philanthropy, Children, Telecommunications, Artificial Intelligence, Family, Infectious Diseases, Consumer, Data Management, Philanthropy, Dental, Technology, Mobile, Wireless, Medical Supplies, General Health, Biotechnology, People with Disabilities, Health, Apps, Applications, Health Technology, Dental care, Boston University, Dentistry, Disability studies, Medicaid, Diabetes, Machine learning, Artificial intelligence, Smartphone, Pediatric dentistry, Disease, Special Olympics, Patient, Caregiver, Multimedia, Oral hygiene, Goldman School

Avēsis and Harmony Health have joined forces to bridge oral healthcare gaps for underserved Medicaid populations with special healthcare needs.

Key Points: 
  • Avēsis and Harmony Health have joined forces to bridge oral healthcare gaps for underserved Medicaid populations with special healthcare needs.
  • The saliva test utilizes adaptive learning to identify oral health conditions, offering a customized preventive oral healthcare plan.
  • “By harnessing the power of innovative technologies like salivary testing and artificial intelligence, we are redefining preventive healthcare.
  • Together, we are committed to empowering patients with proactive, personalized solutions.”
    The multi-state pilot underscores Avēsis’ commitment to improving access to innovative healthcare solutions and reaching diverse patient populations.

BMF receives FDA 510(k) Clearance for UltraThineer Cosmetic Veneer Material

Retrieved on: 
Tuesday, April 23, 2024
Technology, Medical Supplies, FDA, Other Technology, Dental, Health Technology, Health, Cosmetics, Retail, Dental care, Food, Dentistry, Workflow, 3D, BMF, Patient, Dentures, Peking University, Food and Drug Administration

Boston Micro Fabrication (BMF), a leader in advanced manufacturing solutions for ultra-high precision applications, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its innovative UltraThineer™ material used to create the world’s thinnest cosmetic dental veneer.

Key Points: 
  • Boston Micro Fabrication (BMF), a leader in advanced manufacturing solutions for ultra-high precision applications, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its innovative UltraThineer™ material used to create the world’s thinnest cosmetic dental veneer.
  • Further, UltraThineer requires significantly less preparation for dental professionals, allowing preservation of the patient’s original enamel with a more realistic final appearance.
  • "We are thrilled to hear that the UltraThineer veneer has received FDA 510(k) clearance.
  • In addition, BMF is developing complementary cosmetic dentistry offerings in international markets to support both direct-to-patient and provider-enabled access to thinner veneers.

Medical Adhesives & Sealants World Market Report 2024: Remineralizing Agents Being Used to Restore Resin-Based Dental Materials - ResearchAndMarkets.com

Retrieved on: 
Monday, April 22, 2024
Medical Supplies, Health, Internal, Acrylic, Catheter, Polyurethane, Instrument, Metal, Dental, Fibrin, Cosmetics, Skin, Dentistry, USB On-The-Go, Medical device, Polymer, Suture, Plastic surgery, Adhesive, Surgical instrument, Equipment

The "Medical Adhesives & Sealants World Market Report" has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Medical Adhesives & Sealants World Market Report" has been added to ResearchAndMarkets.com's offering.
  • There are several applications for adhesives and sealants the medical sector, including in the areas of dentistry & cosmetics, internal & external surgery and medical devices & equipment.
  • Among these, acrylic, silicone, polyurethane, polyethylene glycol and cyanoacrylate are most widely used materials to make synthetic/semi-synthetic adhesives & sealants.
  • This world market compendium analyzes the market for Medical Adhesives & Sealants at a high level by resin type/sub-type, application, end-use sector and geographic region.

Donor Dash Brings Wyomingites Together to Celebrate the Gift of Life

Retrieved on: 
Saturday, April 20, 2024
Philanthropy, Health, Hospitals, Surgery, Other Philanthropy, Other Health, General Health, University, City, Driver, Pneumonia, Hope, Transplant, Hospital, Heart, Death, Trauma, Paratriathlon, Life, Disease, Family, Patient, Eye, Aneurysm, Organization, Dentistry

“It’s remarkable to see the number of lives saved and healed in Wyoming through the gift of life,” said Jennifer Prinz, president and CEO, Donor Alliance.

Key Points: 
  • “It’s remarkable to see the number of lives saved and healed in Wyoming through the gift of life,” said Jennifer Prinz, president and CEO, Donor Alliance.
  • Wyomingites understand the importance of helping their neighbors and helping their community when they say, ‘yes’ to be an organ, eye and tissue donor at Driver Services.”
    At the 2024 Wyoming Donor Dash, Donor Alliance was honored to host Casper residents Cary Galvin, donor sister, and heart recipient, Jason Wynia.
  • Both Cary and Jason are Donor Alliance advocate for life volunteers who connect Wyomingites to the mission by sharing their stories to inspire residents to register as an organ, eye and tissue donor.
  • Many hospitals and organizations across the region have also been raising Donate Life flags to honor the gift of life.

LIBERTY Dental Plan Contributes $7,500 to the TeamSmile® National Football League (NFL) Event for Child-Focused Dental Programs in Louisiana and Tennessee

Retrieved on: 
Tuesday, April 23, 2024
Managed Care, Sports, General Health, Professional Services, General Sports, Consumer, Football, Health Insurance, Dental, Children, Insurance, Health, NFL, Sport, Education, Dentist, Dentistry

LIBERTY Dental Plan, a leading benefits administrator founded in 2002 by dentists and health industry professionals which currently administers dental benefits in all 50 states, today announced a $7,500 contribution to TeamSmile’s NFL spring/summer 2024 program, supporting solutions for Louisiana and Tennessee children in need to have life-changing dental experiences through the influence of sports.

Key Points: 
  • LIBERTY Dental Plan, a leading benefits administrator founded in 2002 by dentists and health industry professionals which currently administers dental benefits in all 50 states, today announced a $7,500 contribution to TeamSmile’s NFL spring/summer 2024 program, supporting solutions for Louisiana and Tennessee children in need to have life-changing dental experiences through the influence of sports.
  • “At LIBERTY, we strive to make positive, life-changing experiences for our members, especially children,” said Tom Choate, President and CEO of LIBERTY Dental Plan.
  • “This year, we are thrilled to sponsor one of TeamSmile’s NFL events, designed to combine the excitement of sports with the value of a life-long commitment to oral health.
  • We appreciate the opportunity to partner with TeamSmile, which provides children with free dental preventive care, education, and even treatment, if needed.”

AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management

Retrieved on: 
Thursday, April 18, 2024
Health Technology, Clinical Trials, Teens, Cardiology, Parenting, Surgery, Biotechnology, Women, Children, Seniors, Other Science, Health, Research, Men, Family, Consumer, LGBTQ+, Science, Nursing, Medical Supplies, FDA, General Health, Medical Devices, Hospitals, Genetics, Society, Safety, Freezing, Atrial fibrillation, Workflow, LAA, Adolescence, Cardiac surgery, Intercostal nerves, Cryosphere, Pain management, Patient, Physician, Opioid, Temperature, Sympathetic nervous system, Medical college, Dentistry

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device.

Key Points: 
  • AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device.
  • The product is currently in an extended limited launch period in the United States, with full launch expected by the end of the second quarter.
  • “cryoSPHERE+ is a meaningful innovation that I believe will improve patient care, enhance outcomes, and enable physicians to perform procedures with greater ease and confidence,” said Michael Carrel, President and Chief Executive Officer at AtriCure.
  • Because of its long-lasting nature, physicians are adopting Cryo Nerve Block therapy using cryoSPHERE as part of their multi-modal pain management strategy.

Mary Beth Kirkpatrick Honored with Prestigious AAO Service Award

Retrieved on: 
Thursday, April 18, 2024
Software, Practice Management, Data Analytics, Health, Consulting, Professional Services, Technology, Dental, University, Consultant, Ernest, Associate, AAO, Dentistry

We are thrilled to announce that Mary Beth Kirkpatrick, celebrated consultant and founder of Gaidge , has been honored with the 2024 Outstanding Contribution Award by the American Association of Orthodontists (AAO).

Key Points: 
  • We are thrilled to announce that Mary Beth Kirkpatrick, celebrated consultant and founder of Gaidge , has been honored with the 2024 Outstanding Contribution Award by the American Association of Orthodontists (AAO).
  • This annual prestigious award recognizes a non-orthodontist nominee who has profoundly impacted the orthodontic specialty.
  • She ventured into new territories, developing features for orthodontic practice management systems and establishing her own consulting company, Kirkpatrick & Associates.
  • We eagerly anticipate this special moment to honor Mary Beth’s extraordinary achievements and her lasting impact on the orthodontic industry.

Sage Dental Opens Two New Florida Practices

Retrieved on: 
Tuesday, April 16, 2024
General Health, Health, Dental, De novo, Acquisition, Suite, Dentistry, Pediatrics, Orthodontics, Space Coast, DSO

Sage Dental, a leading dental service organization (DSO) committed to providing consistent, high-quality care, as well as non-clinical business and administrative services to affiliated practices, today announced that it has opened two de novo practices in South Tampa and Viera, Florida, bringing the organization to over 120 practices throughout Florida and Georgia.

Key Points: 
  • Sage Dental, a leading dental service organization (DSO) committed to providing consistent, high-quality care, as well as non-clinical business and administrative services to affiliated practices, today announced that it has opened two de novo practices in South Tampa and Viera, Florida, bringing the organization to over 120 practices throughout Florida and Georgia.
  • Equipped with the latest cutting-edge dental technology, the new practices will offer a complete roster of dental services and convenient administrative options, including teledentistry, routine screenings, virtual check-ins, online appointment scheduling, paperless billing, and more.
  • Committed to a modern, family-friendly approach to dentistry, Sage Dental has grown exponentially since its inception over 25 years ago, doubling its total portfolio in 2023.
  • Sage Dental also recently announced the acquisition of Children’s Dentistry in Tampa, Florida, marking the first Sage Dental Kids location dedicated specifically to pediatrics and orthodontics.

Breakthrough Cardiac Study Reveals Long-Term Impact on Post-Transplant Survival: A 2-Year Clinical Investigation Advancing Heart Preservation

Retrieved on: 
Friday, April 12, 2024
Health, Surgery, Clinical Trials, Medical Devices, Mortality, MCS, Ice, Hospital, Heart, Survival, Transport, Heart transplantation, Transplant, Patient, ECMO, Massachusetts General Hospital, Dentistry

Notably, the unprecedented study represents the first time any medical device technology has ever demonstrated statistically significant improvements in 2-year survival following heart transplantation.

Key Points: 
  • Notably, the unprecedented study represents the first time any medical device technology has ever demonstrated statistically significant improvements in 2-year survival following heart transplantation.
  • “This breakthrough is game-changing," said Dr. Scott Silvestry, a lead investigator and renowned cardiac surgeon with decades of clinical experience.
  • “This study indicates that the SherpaPak System can attenuate the risks of ischemic time through controlled hypothermic and isobaric preservation.
  • The intended organ storage time for the Paragonix SherpaPak™ Cardiac Transport System is up to 4 hours.

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation

Retrieved on: 
Thursday, April 11, 2024
Health, Surgery, Genetics, Clinical Trials, Research, Science, Biotechnology, Nucleic acid thermodynamics, University, NTRA, Risk, MD, Transplant, EGFR, DNA, Oportunidades, Patient, Microbiology, Biopsy, Maryland School, ProActive, Dentistry

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection.

Key Points: 
  • Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney donor-derived cfDNA (dd-cfDNA) test as a leading indicator of kidney transplant rejection.
  • The ProActive study is the largest prospective dd-cfDNA study in kidney transplant recipients, with roughly 5,000 patients enrolled at 54 participating transplant centers.
  • These data further support the Prospera Kidney test’s value as an early indicator of rejection vs biopsy.
  • Natera remains excited to continue pursuing additional clinical evidence and optimizing the management of kidney transplant patients for improved long-term outcomes.”